These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

66 related articles for article (PubMed ID: 14734678)

  • 21. SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation.
    Lahoutte T; Caveliers V; Camargo SM; Franca R; Ramadan T; Veljkovic E; Mertens J; Bossuyt A; Verrey F
    J Nucl Med; 2004 Sep; 45(9):1591-6. PubMed ID: 15347729
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [A comparison on radiochemical behavior and biological property of antisense oligonucleotide labeled with technetium-99m by two methods: NHS-MAG3 versus SHNHP].
    Li Y; Tan T; Zheng J; Zhang C
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2008 Aug; 25(4):889-93, 902. PubMed ID: 18788302
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Multicenter trial validation of a camera-based method to measure Tc-99m mercaptoacetyltriglycine, or Tc-99m MAG3, clearance.
    Taylor A; Manatunga A; Morton K; Reese L; Prato FS; Greenberg E; Folks R; Kemp BJ; Jones ME; Corrigan PE; Galt J; Eshima L
    Radiology; 1997 Jul; 204(1):47-54. PubMed ID: 9205222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of renal transplant survival from early postoperative radioisotope studies.
    Russell CD; Yang H; Gaston RS; Hudson SL; Diethelm AG; Dubovsky EV
    J Nucl Med; 2000 Aug; 41(8):1332-6. PubMed ID: 10945523
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonradioactive monitoring of organic and inorganic solute transport into single Xenopus oocytes by capillary zone electrophoresis.
    Nussberger S; Foret F; Hebert SC; Karger BL; Hediger MA
    Biophys J; 1996 Feb; 70(2):998-1005. PubMed ID: 8789117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Simultaneous measumrement of the renal excretion of 131I-hippuran and 99mTc-MAG3].
    Schroth HJ; Bialy J; Bühler M; Peters JW; Rink T; Schmidt M; Garth H
    Nuklearmedizin; 1994 Jun; 33(3):113-8. PubMed ID: 8090625
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How gender and age affect iodine-131-OIH and technetium-99m-MAG3 clearance.
    Bagni B; Bagni I; Orsolon P; Corazzari T
    J Nucl Med Technol; 2000 Sep; 28(3):156-8. PubMed ID: 11001496
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of renal scintigraphy and clearance with technetium-99m-MAG3 and iodine-123-hippurate in patients with renal disorders.
    Müller-Suur R; Bois-Svensson I; Mesko L
    J Nucl Med; 1990 Nov; 31(11):1811-7. PubMed ID: 2146371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Determinations of MAG3 clearance according to the whole-body principle and to related methods].
    Sonntag A
    Nuklearmedizin; 1996 Aug; 35(4):132-9. PubMed ID: 9005407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent.
    Okarvi SM; al-Jammaz I
    Anticancer Res; 2003; 23(3B):2745-50. PubMed ID: 12894569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of Tc-99m DTPA and Tc-99m MAG3 perfusion time-activity curves in patients with renal allograft dysfunction.
    Aktaş A; Aras M; Colak T; Gençoğlu A; Karakayali H
    Transplant Proc; 2006 Mar; 38(2):449-53. PubMed ID: 16549144
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of 99mTc-MAG3-annexin V: influence of the chelate on in vitro and in vivo properties in mice.
    Vanderheyden JL; Liu G; He J; Patel B; Tait JF; Hnatowich DJ
    Nucl Med Biol; 2006 Jan; 33(1):135-44. PubMed ID: 16459269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Bayesian 3-compartment model for 99mTc-MAG3 clearance.
    Russell CD
    J Nucl Med; 2003 Aug; 44(8):1357-61. PubMed ID: 12902428
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Technetium-99m-N,N-ethylenedicysteine--a comparative study of renal scintigraphy with technetium-99m-MAG3 and iodine-131-OIH in patients with obstructive renal disease.
    Ozker K; Onsel C; Kabasakal L; Sayman HB; Uslu I; Bozluolçay S; Cansiz T; Kapicioğlu T; Urgancioğlu I
    J Nucl Med; 1994 May; 35(5):840-5. PubMed ID: 8176468
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacokinetics of technetium-99m-MAG3 in humans.
    Bubeck B; Brandau W; Weber E; Kälble T; Parekh N; Georgi P
    J Nucl Med; 1990 Aug; 31(8):1285-93. PubMed ID: 2143528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Organic anion transporter 3 (Slc22a8) is a dicarboxylate exchanger indirectly coupled to the Na+ gradient.
    Sweet DH; Chan LM; Walden R; Yang XP; Miller DS; Pritchard JB
    Am J Physiol Renal Physiol; 2003 Apr; 284(4):F763-9. PubMed ID: 12488248
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissular distributions and kinetics of two renal 99mTc-radiopharmaceuticals in rat.
    Bonnin F; Petiet A; Petegnief Y; Colas-Linhart N; Bok B
    Cell Mol Biol (Noisy-le-grand); 2001 May; 47(3):437-42. PubMed ID: 11441950
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical evaluation of technetium-99m-L,L-ethylenedicysteine in patients with chronic renal failure.
    Prvulovich EM; Bomanji JB; Waddington WA; Rudrasingham P; Verbruggen AM; Ell PJ
    J Nucl Med; 1997 May; 38(5):809-14. PubMed ID: 9170451
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of technetium-99m-L,L-EC in renal transplant recipients: a comparative study with technetium-99m-MAG3 and iodine-125-OIH.
    Stoffel M; Jamar F; Van Nerom C; Verbruggen A; Mourad M; Leners N; Squifflet JP; Beckers C
    J Nucl Med; 1994 Dec; 35(12):1951-8. PubMed ID: 7989976
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reproducibility of technetium-99m-MAG3 clearance using the Bubeck method.
    Werner E; Blasl C; Reiners C
    J Nucl Med; 1998 Jun; 39(6):1066-9. PubMed ID: 9627345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.